PLoS ONE (Mar 2011)

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.

  • Panagiotis A Konstantinopoulos,
  • Stephen A Cannistra,
  • Helen Fountzilas,
  • Aedin Culhane,
  • Kamana Pillay,
  • Bo Rueda,
  • Daniel Cramer,
  • Michael Seiden,
  • Michael Birrer,
  • George Coukos,
  • Lin Zhang,
  • John Quackenbush,
  • Dimitrios Spentzos

DOI
https://doi.org/10.1371/journal.pone.0018202
Journal volume & issue
Vol. 6, no. 3
p. e18202

Abstract

Read online

Public data integration may help overcome challenges in clinical implementation of microarray profiles. We integrated several ovarian cancer datasets to identify a reproducible predictor of survival.Four microarray datasets from different institutions comprising 265 advanced stage tumors were uniformly reprocessed into a single training dataset, also adjusting for inter-laboratory variation ("batch-effect"). Supervised principal component survival analysis was employed to identify prognostic models. Models were independently validated in a 61-patient cohort using a custom array genechip and a publicly available 229-array dataset. Molecular correspondence of high- and low-risk outcome groups between training and validation datasets was demonstrated using Subclass Mapping. Previously established molecular phenotypes in the 2(nd) validation set were correlated with high and low-risk outcome groups. Functional representational and pathway analysis was used to explore gene networks associated with high and low risk phenotypes. A 19-gene model showed optimal performance in the training set (median OS 31 and 78 months, p < 0.01), 1(st) validation set (median OS 32 months versus not-yet-reached, p = 0.026) and 2(nd) validation set (median OS 43 versus 61 months, p = 0.013) maintaining independent prognostic power in multivariate analysis. There was strong molecular correspondence of the respective high- and low-risk tumors between training and 1(st) validation set. Low and high-risk tumors were enriched for favorable and unfavorable molecular subtypes and pathways, previously defined in the public 2(nd) validation set.Integration of previously generated cancer microarray datasets may lead to robust and widely applicable survival predictors. These predictors are not simply a compilation of prognostic genes but appear to track true molecular phenotypes of good- and poor-outcome.